Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid and Teriparatide Combination in Severe Osteoporosis
NCT00439244Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2006
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of zoledronic acid in osteoporosis (3 arms), sponsored by Novartis. Primary endpoint: Percent Change From Baseline in Lumbar Spine Bone Mineral Density at 52 weeks. Started Dec 2006; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00439244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00439244.